Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.66 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.66 |
| ▸ | DRD1 | P21728 | 1/20 | 0.66 |
| ▸ | MC5R | P33032 | 1/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.66 |
| ▸ | CCR2 | P41597 | 1/20 | 0.66 |
| ▸ | HTR6 | P50406 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.66 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7935498 | 0.90 | ALDH1A1 (0.75) | FBP1ALDH1A1HSD17B10HPGDADRA2A | |
| SCHEMBL7938696 | 0.87 | FBP1 (0.71) | FBP1ALDH1A1HSD17B10HPGDADRA2A | |
| SCHEMBL7935808 | 0.87 | FBP1 (0.71) | FBP1ALDH1A1HSD17B10HPGDADRA2A | |
| SCHEMBL7938987 | 0.85 | FBP1 (0.69) | FBP1ALDH1A1HSD17B10HPGDADRA2A | |
| SCHEMBL7935433 | 0.85 | FBP1 (0.69) | FBP1ALDH1A1HSD17B10HPGDADRA2A | |
| SCHEMBL7926908 | 0.85 | FBP1 (0.69) | FBP1ALDH1A1HSD17B10HPGDADRA2A | |
| SCHEMBL7936753 | 0.85 | FBP1 (0.69) | FBP1ALDH1A1HSD17B10HPGDADRA2A | |
| SCHEMBL1133179 | 0.85 | FBP1 (0.69) | FBP1ALDH1A1HSD17B10HPGDADRA2A | |
| SCHEMBL29113948 | 0.84 | FBP1 (0.77) | FBP1ALDH1A1HSD17B10HPGDADRA2A | |
| SCHEMBL745752 | 0.83 | CYP1A2 (0.80) | FBP1ALDH1A1HSD17B10HPGDADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367051-B2 | Preparation of functional gel particles with a dual crosslink network | CARNEGIE MELLON UNIVERSITY (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367051-B2 | Preparation of functional gel particles with a dual crosslink network | CARNEGIE MELLON UNIVERSITY (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20100143286-A1 | Preparation of functional gel particles with a dual crosslink network | CARNEGIE MELLON UNIVERSITY (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100143286-A1 | Preparation of functional gel particles with a dual crosslink network | CARNEGIE MELLON UNIVERSITY (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2008057163-A2 | PREPARATION OF FUNCTIONAL GEL PARTICLES WITH A DUAL CROSSLINK NETWORK | CARNEGIE MELLON UNIVERSITY (US) | 2008-05-15 | — | — | WO | disclosed |
| EP-0590457-B1 | Benzothiazole derivatives as vulcanisation accelerators suitable for the introduction of polar substituents | BAYER AG (DE) | 2000-12-06 | — | — | EP | disclosed |
| US-6140427-A | 2-(SUBSTITUTED ALKYLTHIO)BENZOTHIAZOLE DERIVATIVES WHICH EFFECT CHAIN TRANSFER OF RUBBER SIDE CHAINS DURING VULCANIZATION | BAYER AG (DE) | 2000-10-31 | — | — | US | disclosed |
| EP-0590457-A1 | Benzothiazole derivatives as vulcanisation accelerators suitable for the introduction of polar substituents | BAYER AG (DE) | 1994-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143286-A1 | Preparation of functional gel particles with a dual crosslink network | PLG, F2, PLAT | FBP1 3613/4885ALDH1A1 2150/4885HSD17B10 3408/4885 |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | LSS, ABCG2, SELL | FBP1 3149/4885ALDH1A1 533/4885HSD17B10 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.